Milton Keynes, United Kingdom
Emmes' Rare Disease and Pediatric Center is a global, full-service Contract Research Organization (CRO) focused on advancing public health and biopharmaceutical innovation. Following the acquisition of Orphan Reach, it now operates as part of Emmes, with a particular emphasis on accelerating the clinical development of orphan drugs and facilitating patient access to urgently needed new treatments for rare conditions.
By offering comprehensive global clinical development services, Emmes aims to prioritize patient recruitment and retention for its innovative biotech clients. The company boasts a far-reaching infrastructure that grants access to rare disease patients in over 100 countries worldwide, with Project Management teams strategically located in Europe, the USA, and Asia. Their collective expertise accelerates access to new drugs across various therapeutic areas.
Through the integration of Emmes' strategic drug development and advanced statistical capabilities with the patient-centered global operational experience of Orphan Reach, the company solidifies its position as a leader in rare and orphan disease research. This positioning aligns with their vision to introduce new treatment options for patients in need.
As an investor or venture capital firm, the analysis showcases Emmes' Rare Disease and Pediatric Center's emphasis on global clinical development for rare diseases, highlighting their comprehensive services, extensive geographic reach, and strategic positioning in the biotechnology industry. The company's recent acquisition and integration of Orphan Reach further strengthens its capabilities, making it an attractive investment opportunity in the rapidly evolving field of rare disease research and drug development.
